Questions for you:
- Where in your work do you try to predict the right answer in advance, when generating a range of options and selecting the one that works might be more effective?
- How does your organisation currently treat the resources it invests in things that don’t pan out? As waste, or as the necessary cost of a functioning discovery process?
- Can you think of a situation where the inefficiency of trying many things simultaneously was actually the point, not a problem to be solved?
Organisational applications:
Portfolio thinking as an immune system strategy: The T-cell story makes explicit what portfolio theory implies but rarely states so plainly: that in genuinely uncertain environments, the only reliable defence is diversity across a large number of low-cost options rather than concentration in a single high-confidence bet. Most organisations do the opposite, running a small number of large, well-specified initiatives whose scope and budget reflect confidence that the right answer has already been identified.
An immune system logic would suggest smaller, more numerous experiments with a clear mechanism for identifying and cloning the ones that work, and a genuine tolerance for the high proportion that will not. The wasteful-seeming majority of T-cells that never encounter a matching threat is not a design flaw; it is what makes the system functional.
Distinguishing prediction from preparation: The story’s central contrast is between a system that tries to anticipate what threat it will face, which the immune system cannot do, and one that prepares for a wide range of possibilities instead. Organisations tend to conflate strategic planning with prediction: the plan identifies what will happen and optimises for it. In stable, low-uncertainty environments, this is sensible. In volatile ones, it is closer to the pre-immune-system approach, concentrated, fragile, and dependent on the threat being one you have already imagined.
The more useful question in uncertain conditions is not “what will happen?” but “what range of things might happen, and how do we ensure we have something that works across that range?” Scenario planning, red-teaming, and pre-mortem analysis are all partial answers; the T-cell model suggests the answer may need to be more systematic and more wasteful than most organisations are currently comfortable with.
The Netflix thumbnail analogy and the discipline of testing rather than deciding: The story draws a direct parallel between T-cell recombination and Netflix’s thumbnail-testing approach: generate variation, expose it to real conditions, clone what works. The same logic applies to any situation where the right answer depends on an audience or market whose preferences cannot be accurately predicted in advance.
The organisational obstacle is usually not technical but cultural: a preference for deciding over testing, driven partly by cost concerns and partly by the discomfort of admitting that the best approach is not yet known. Teams that can frame testing as the decision, rather than as a precursor to the real decision, tend to produce better outcomes in proportion to the degree of uncertainty they are operating in.
Further reading
On the biology of randomness and immune diversity:
The Compatibility Gene by Daniel M. Davis. Davis covers the genetics of immune response, including the random recombination processes behind T-cell receptor diversity, in a way that is accessible to non-specialists while remaining scientifically precise.
The Beautiful Cure by Daniel M. Davis. A broader account of how the immune system works and how understanding it has changed medicine, with useful material on the role of chance in biological defence mechanisms.
On portfolio thinking and diversity under uncertainty:
The Wisdom of Crowds by James Surowiecki. Surowiecki’s argument for aggregating diverse, independent judgements over expert consensus is a social-system parallel to the T-cell logic, where diversity of response is itself the mechanism rather than a limitation to be overcome.
Antifragile: Things That Gain from Disorder by Nassim Nicholas Taleb. Taleb’s account of systems that benefit from volatility and uncertainty is the most direct organisational parallel to the immune system strategy, particularly his argument for preferring many small bets over few large ones in high-variance environments.
On experimentation as strategy:
The Lean Startup by Eric Ries. Ries’s framework for validated learning through rapid experimentation is an application of immune system logic to product development, though the book rarely frames it in those terms.
Experimentation Works: The Surprising Power of Business Experiments by Stefan Thomke. A research-based account of how organisations that systematically run large numbers of experiments outperform those that rely on expert judgement, with direct relevance to the clone-what-works mechanism the story describes.
About the image
A visualisation of what a T-Cell would look like if it were made a great deal bigger.
Montage by Matt Ballantine, 2026
Random the Book 